Literature DB >> 6245674

Immune reactions in epidermodysplasia verruciformis.

S Pyrhönen, S Jablonska, S Obałek, E Kuismanen.   

Abstract

Serum antibodies against human papilloma virus have been measured using immunodiffusion and enzyme linked immunosorbent assay in twelve patients with epidermodysplasia verruciformis (EV). The results were compared with those from sixty-six patients with other types of human papilloma virus diseases. Antibody prevalences were slightly lower in patients with EV than in the control patients. More remarkable was the difference between EV patiens and control subjects in tests of non-specific cell-mediated immunity, which was markedly depressed in the majority of patients with EV, but in the main preserved in patients with common warts. No specific immunological parameter was shown to be associated with malignant conversion of EV lesions, but malignancy was linked to the character of the inducing virus, and particularly to HPV type 5.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245674     DOI: 10.1111/j.1365-2133.1980.tb08136.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

1.  Epidermodysplasia verruciformis (L-L, 1922) in a patient with systemic lupus erythematosus.

Authors:  T Tanigaki; R Kanda; K Sato
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

Review 2.  Immunopathology of papillomavirus-induced tumors in different tissues.

Authors:  S Jablonska; G Orth; M A Lutzner
Journal:  Springer Semin Immunopathol       Date:  1982

Review 3.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

4.  Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.

Authors:  J C Steele; T Stankovic; P H Gallimore
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

5.  Epidermodysplasia verruciformis induced by a new human papillomavirus (HPV-8). Report of a case without immune dysfunction. Effect of treatment with an aromatic retinoid.

Authors:  A L Claudy; J L Touraine; D Mitanne
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

Review 6.  The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections.

Authors:  Maciej Lazarczyk; Patricia Cassonnet; Christian Pons; Yves Jacob; Michel Favre
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

7.  Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins.

Authors:  S A Jenison; J M Firzlaff; A Langenberg; D A Galloway
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

8.  EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation.

Authors:  Maciej Lazarczyk; Cécile Dalard; Myriam Hayder; Loïc Dupre; Béatrice Pignolet; Slawomir Majewski; Francoise Vuillier; Michel Favre; Roland S Liblau
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.